ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan#IL-13R抗体#
$15M UF, $123.5M biobucks
TREK-AD topline data early July查看全文
亚狮康药业(ASLN)2023-06-22 20:35
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-23-171833 Act: 34 Size: 43 KB 网页链接查看全文
亚狮康药业(ASLN)2023-04-28 19:33
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950170-23-015479 Act: 34 Size: 380 KB 网页链接查看全文
亚狮康药业(ASLN)2023-04-27 04:33
$亚狮康药业(ASLN)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001722926-23-000001 Act: 33 Size: 13 KB 网页链接查看全文
亚狮康药业(ASLN)2023-04-27 05:33
$亚狮康药业(ASLN)$ F-6EF Registration of American Depository Receipt shares, immediately effective Accession Number: 0001193805-23-000606 Act: 33 Size: 191 KB 网页链接查看全文
亚狮康药业(ASLN)2023-04-07 18:06
$亚狮康药业(ASLN)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000848 Act: 33 Size: 1 KB 网页链接查看全文
亚狮康药业(ASLN)2023-04-07 18:06
$亚狮康药业(ASLN)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000850 Act: 33 Size: 1 KB 网页链接查看全文
亚狮康药业(ASLN)2023-03-24 19:06
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950170-23-009592 Act: 34 Size: 514 KB 网页链接查看全文
chuminhua2023-07-07 12:14
7/6,ASLAN Pharmaceuticals$亚狮康药业(ASLN)$ 报告称,其阻断 IL-4 和 IL-13 信号传导的在研药物eblasakimab,在特应性皮炎患者的 IIb 期试验中达到了主要终点。 首席执行官 Carl Firth 表示:“我们首次制定了每月一次的给药方案,该方案有可能提高当前生物制剂治疗特应性皮炎的疗效和安全性。...查看全文
郁闷的鞋套-2023-07-07 07:33
$亚狮康药业(ASLN)$
根据周四的新闻稿,该疗法在四个给药组中的三个达到了主要目标,每四周或每两周给药一次,剂量分别为600 mg、400 mg或300 mg。
在每四周给药一次的600 mg组中,依布拉沙单抗表现最好,62.7%的患者达到了EASI-75评分,而安慰剂组的这一比例为30.7%,p值为0.0041。34.1%...查看全文
郁闷的鞋套-2023-07-07 07:28
$亚狮康药业(ASLN)$ 在周四上午的一次电话会议上,分析人士对阿斯兰试验中的高安慰剂率提出了质疑。相比之下,近十年前Dupixent的IIb期试验在vIGA-AD上的安慰剂率为2%。
Firth指出,最近的特应性皮炎试验显示,安慰剂的使用率要高得多,这可能是因为更难找到没有尝试过Dupixent的患者,尤其是...查看全文
产业链观察2023-07-06 20:17
#药闻简讯# 2023年7月6日,以免疫学为重点的临床阶段生物公司$亚狮康药业(ASLN)$ 今天宣布了其对中重度特应性皮炎(AD)成年患者进行的2b期剂量范围研究TREK-AD(TRials with EblasaKimab in Atopic Dermatitis)的积极顶线数据。
Eblasakimab在第16周与安慰剂相比达到了湿疹面积和严重程度指...查看全文
SeekingBiotech2023-06-23 21:04
$亚狮康药业(ASLN)$
ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan#IL-13R抗体#
$15M UF, $123.5M biobucks
TREK-AD topline data early July查看全文
牛唐2021-02-26 14:52
医药板块观察(2021.02.25)
1、大盘回调,哪些医药标的需要回避?
2、又一准备放量上攻而被错杀白马股,是否值得入手?
3、$亚狮康药业(ASLN)$ 是数据泄露了,还是提前诱多?
$恒瑞医药(SH600276)$ $迈瑞医疗(SZ300760)$查看全文
牛唐2021-01-12 10:36
医药板块速评(2021.01.11)
1、$Karyopharm(KPTI)销售不及预期,可以抄底?
2、$亚狮康药业(ASLN)数据发布在即,可以赌一把?
3、$Aurinia制药(AUPH)PDUFA审批在即,是否继续持有?
$五粮液(SZ000858)$ $立讯精密(SZ002475)$ $百济神州(06160)$查看全文
$亚狮康药业(ASLN)$ F-3 Registration statement by foreign private issuers Accession Number: 0001193125-24-076568 Act: 33 Size: 470 KB 网页链接
$亚狮康药业(ASLN)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-24-024796 Act: 34 Size: 67 KB 网页链接
$亚狮康药业(ASLN)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000929638-24-001052 Act: 34 Size: 70 KB 网页链接
$亚狮康药业(ASLN)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0000950170-24-031128 Act: 33 Size: 993 KB 网页链接
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950170-24-030507 Act: 34 Size: 697 KB 网页链接
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950170-24-028920 Act: 34 Size: 100 KB 网页链接
$亚狮康药业(ASLN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001140361-24-008027 Act: 34 Size: 120 KB 网页链接
$亚狮康药业(ASLN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000921895-24-000460 Act: 34 Size: 285 KB 网页链接
$亚狮康药业(ASLN)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001610520-24-000023 Act: 34 Size: 9 KB 网页链接
$亚狮康药业(ASLN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0000950170-24-006838 Act: 34 Size: 333 KB 网页链接